RxDoctor Payments Data

Niani Conerly, APRN

Nurse Practitioner · Downey, CANPI 1649742206

Payments from drug & device makers

$2,252in general payments, 2019–2025

Across 69 payments — averaging $32.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$551
  • Merz North America, Inc.$491
  • Amgen$466
  • Galderma Laboratories, L.p.$199
  • VYNE Pharmaceuticals Inc.$125
  • Incyte Corporation$117
  • plus $303 from 10 others

What the payments were for

  • Travel & lodging$26312%
  • Food & beverage$1,98988%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,252 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$6,345
Medicare patients
26
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast47$212,461
Humira(Cf) PenAdalimumab17$112,622
Taltz AutoinjectorIxekizumab14$93,149
Dupixent PenDupilumab19$69,126
Clindamycin Phosphate63$5,186
Ketoconazole249$4,586
Clobetasol Propionate234$3,176
Imiquimod94$3,098
Pimecrolimus11$2,896
Betamethasone Dipropionate63$2,558
Metronidazole57$2,447
Tacrolimus34$1,588
Ciclopirox82$1,293
Tretinoin22$1,272
Fluorouracil17$1,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$466$212,46147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →